Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat Media Global Medical: This REIT Just Got a 30% Price TargetWritten by Sam Quirke. Published 10/20/2025. 
Key Points - Global Medical REIT’s multi-year downtrend may finally be ending.
- Fresh analyst upgrades are indicating as much as a nearly 30% upside from current levels.
- A juicy 9.3% dividend yield adds to an increasingly attractive risk/reward setup.
Real estate investment trusts (REITs) are often a favorite among income investors. They offer regular dividends, provide easy exposure to tangible assets, and can serve as a natural hedge against inflation. Within that universe, Global Medical REIT Inc. (NYSE: GMRE) stands out as a niche player focused on healthcare properties. Its portfolio includes medical office buildings, outpatient facilities, and specialty care centers — all backed by long-term leases and stable tenants. Frustratingly for investors, however, that brick-and-mortar stability hasn't translated into shareholder returns. Global Medical's shares have been in a persistent decline since December 2021, losing more than 60% of their value. Several factors contributed to this slide, and the stock hit fresh all-time lows earlier this month. Gallup reports that two-thirds of Americans now view socialism favorably — a shocking shift that one analyst says signals a much deeper and more dangerous transformation underway. Porter Stansberry calls it The Final Displacement — a once-in-a-century realignment of technology, society, and economics that could create vast new wealth for some while devastating millions of others. His new documentary breaks down the warning signs, the accelerating pace of this change, and how to prepare before it reshapes the world around us. Click here to stream The Final Displacement for free After years of relentless selling, there are finally signs of a bottom forming. With several analysts turning more bullish and the technical picture improving, there are reasons to think Global Medical's long-awaited recovery may be taking shape. Let's take a closer look. A Brutal Downtrend, But a Clear Floor Emerging Much of the stock's decline can be attributed to higher interest rates and investor skepticism toward debt-heavy real estate names, which made bears particularly focused on Global Medical. It didn't help that leadership trimmed the dividend by 29% earlier this year, a move that shook investor confidence while the stock was consolidating. Still, the stock may have found a floor. The $30 level has emerged as critical support — it's where selling pressure eased last May, and buyers have stepped in again. Over the past week, shares have bounced sharply off $30, suggesting institutional investors may be quietly building positions. Momentum indicators are also starting to favor bulls. The RSI has rebounded from deeply oversold levels, and the MACD is nearing a bullish crossover. After nearly four years of downward pressure, Global Medical's chart shows early signs of a low. For sidelined investors, that could be an interesting entry point. Analysts Are Turning Bullish Again An ongoing shift in Wall Street sentiment is strengthening that case. Earlier this week, Citizens JMP upgraded Global Medical from Market Perform to Outperform and set a new price target of $40. From the stock's close on Wednesday, that implies upside of nearly 30%. Their bullish update echoed Zacks Research, which raised its rating to Strong Buy last month, highlighting growing optimism across the analyst community. There appears to be a sense that much of the downside has been priced in, and the company's improving balance sheet and a more supportive macro backdrop are reasons for optimism. Indeed, the broader environment for REITs is improving. Expectations of future rate cuts should relieve yield-sensitive stocks like Global Medical, and the recently announced $50 million share-repurchase program provides additional support. The new CEO's focus on deleveraging signals management is intent on turning the page after a painful few years for shareholders. For investors considering a position around $30, the company's 9.31% dividend yield is particularly compelling. It offers an attractive income stream even if a recovery takes time. Risks Remain, But the Setup Is Compelling That said, risks remain. Global Medical is still highly sensitive to interest-rate moves, and while the Fed appears to be in a softening cycle, the timing is uncertain. The company also faces lingering investor skepticism after a prolonged selloff while the broader market rallied. Even so, the risk/reward looks favorable at these levels. After a roughly 60% peak-to-trough decline, much of the bad news may already be priced in, and recent analyst upgrades suggest sentiment is beginning to shift. If shares can hold above $30 through the rest of October, it would help confirm a durable base. From there, the technicals and analyst targets point to room for a meaningful rebound into year-end.
| 
Post a Comment
Post a Comment